Hyperglycemia is an important risk factor for poor clinical outcomes in patients with acute
myocardial infarction (AMI). The relative superiority of the long-term clinical outcomes of durable-
polymer (DP) -based and biodegradable-
polymer (BP) -based newer-generation
drug-eluting stents (DESs) after successful
percutaneous coronary intervention (PCI) in patients with AMI and
prediabetes is not well established. We compared the clinical outcomes in such patients between DP-based and BP-based newer-generation DESs.A total of 4,377 patients with AMI and
prediabetes were divided into the following two groups: the DP-DES group (n = 3,775;
zotarolimus-eluting
stents [ZES; n = 1,546] and
everolimus-eluting
stents [EES; n = 2,229]) and the BP-DES group (n = 602; biolimus-eluting
stents [
BES]). The primary endpoint was the occurrence of
major adverse cardiac events (MACEs), defined as all-cause death, recurrent
myocardial infarction (re-MI), or any repeat revascularization. The secondary endpoint was the occurrence of
stent thrombosis (ST).The 2-year adjusted hazard ratio (aHR) of MACEs for ZES versus EES, ZES versus
BES, EES versus
BES, and ZES/EES versus
BES (aHR: 1.125; 95% confidence interval [CI], 0.834-1.518; P = 0.440) were similar. The cumulative incidence of ST was also comparable between the DP-DES and BP-DES groups (aHR: 1.407; 95% CI, 0.476-4.158; P = 0.537). Moreover, the 2-year aHRs of all-cause death, CD, re-MI, target lesion revascularization (TLR), target vessel revascularization (TVR), and non-TVR were similar.Patients with AMI and
prediabetes who received DP-DES or BP-DES during PCI showed comparable safety and efficacy during the 2-year follow-up period.